<DOC>
	<DOCNO>NCT00416312</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody , iodine I 131 tositumomab yttrium Y 90 ibritumomab tiuxetan , find cancer cell carry cancer-killing substance without harm normal cell . This may effective treatment non-Hodgkin 's lymphoma . PURPOSE : This clinical trial study side effect , best dose , well iodine I 131 tositumomab yttrium Y 90 ibritumomab tiuxetan work treat patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Iodine I 131 Tositumomab Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine relationship estimate absorb dose tumor response use different dosimetric methodology patient non-Hodgkin 's lymphoma treat iodine I 131 tositumomab yttrium Y 90 ibritumomab tiuxetan . - Determine relationship estimate absorbed dose normal organ toxicity use different dosimetric methodology patient . Secondary - Assess difference dose-response relationship dosimetric methodology patient . - Assess influence prior therapy dose-response relationship hematologic toxicity patient . OUTLINE : Patients stratify accord plan radioimmunotherapy treatment ( iodine I 131 tositumomab v yttrium Y 90 ibritumomab tiuxetan ) . - Stratum 1 : Patients receive dosimetric rituximab IV follow indium In 111 ( ^111In ) ibritumomab tiuxetan IV 10 minute day 1 . Patients undergo positron emission tomography ( PET ) /CT scan single-photon emission compute tomography ( SPECT ) /CT scan 2-24 , 48-72 , 90-120 hour ^111In ibritumomab tiuxetan administration . Patients acceptable biodistribution receive therapeutic rituximab IV follow yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 7-9 . - Stratum 2 : Patients receive dosimetric tositumomab IV 60 minute follow iodine I 131 ( ^131I ) tositumomab IV 20 minute day 0 . Patients undergo PET/CT scan SPECT/CT scan day 0 ; 2 , 3 4 ; 6 7 . Patients acceptable biodistribution receive therapeutic tositumomab IV 60 minute follow ^131I tositumomab IV 20 minute approximately day 7 . In stratum , blood collect baseline measure FLT-3 level . All patient also undergo baseline PET/CT scan . After completion study treatment , patient follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 88 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonHodgkin 's lymphoma Measurable disease CT scan nuclear medicine image Eligible , standard care criterion , iodine I 131 tositumomab yttrium Y 90 ibritumomab tiuxetan treatment PATIENT CHARACTERISTICS : No malignancy within past 3 year except basal cell carcinoma squamous cell carcinoma skin situ carcinoma cervix Not pregnant nursing Fertile patient must use effective contraception No alcoholism drug abuse within past 2 year No severe emotional , behavioral , psychiatric problem would limit study compliance PRIOR CONCURRENT THERAPY : No concurrent participation another investigational drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
</DOC>